Phoenix New Media Hong Kong Stock Market | Donui Pharmaceutical (02348) announced that the company has been informed by Congrong Oriental that a key registered phase III clinical trial of PCSK9 McAb (AK102) in the treatment of primary hypercholesterolemia and mixed hyperlipidemia in China has been completed ahead of schedule.
This clinical trial is one of three large-scale key registered clinical trials of inuximab in the treatment of primary hypercholesterolemia and mixed hyperlipidemia. The clinical trial is designed to cover the unmet clinical needs of a wide range of people, and is designed to evaluate the lipid-lowering efficacy and safety of inuximab in patients with cardiovascular very high-risk, high-risk and medium-low risk hyperlipidemia for a long time. To provide more basis for supporting the launch of products.